Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
Harry P. Erba(Michigan Center for Translational Pathology), Richard F. Schlenk(German Cancer Research Center), Po‐Nan Wang(Chang Gung Memorial Hospital), Jörge E. Cortes(Augusta University Health), Arnaud Lesegretain(Daiichi Sankyo (United States)), Aziz Benzohra(Daiichi Sankyo (United States)), Alexander E. Perl(University of Pennsylvania), Mikkael A. Sekeres(University of Miami), James Hanyok(Daiichi Sankyo (United States)), Jaime E Connolly Rohrbach(Daiichi Sankyo (United States)), Elżbieta Patkowska(Instytut Hematologii i Transfuzjologi), Yasser Mostafa Kamel(Daiichi Sankyo (United States)), Tsvetomir Mitov(Daiichi Sankyo (United Kingdom)), Radovan Vrḫovac(University Hospital Centre Zagreb), Sergio Amadori(Polyclinic Medical Center), Jianxiang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Mark J. Levis(Sidney Kimmel Cancer Center), Hee‐Je Kim(St. Mary's Hospital), Li Liu(Daiichi Sankyo (United States)), Hervé Dombret(University of London Institute in Paris), Pavel Žák(University Hospital Hradec Králové), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 387
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k